FLERIDA TAN: Open Payments
NPI 1316479991 · MAYS LANDING, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,148 in 155 payments from 20 companies in 2025. Trend: 2023 $935 · 2024 $1,839 · 2025 $2,148
Food & beverage: $2,148
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 30 | $305 |
| Janssen Biotech, Inc. | 10 | $286 |
| UCB, Inc. | 16 | $249 |
| ABBVIE INC. | 22 | $238 |
| LEO Pharma Inc. | 20 | $170 |
| Lilly USA, LLC | 11 | $164 |
| Galderma Laboratories, L.P. | 6 | $104 |
| PFIZER INC. | 6 | $98 |
| Incyte Corporation | 5 | $88 |
| Organon LLC | 7 | $85 |
Products named: TREMFYA, Bimzelx, COSENTYX, ADBRY, SKYRIZI, TALTZ, Rhapsido, NEMLUVIO.
Industry payments across NJ — which companies pay providers there.
